MorphoSys (MOR)
(Delayed Data from NSDQ)
$18.55 USD
-0.25 (-1.33%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $18.61 +0.06 (0.32%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MOR 18.55 -0.25(-1.33%)
Will MOR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MOR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MOR
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
MOR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Novartis (NVS) to Undertake Job Cuts in Development Department
Other News for MOR
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
Novartis AG Takes Major Stake in MorphoSys
IN BRIEF: Novartis to squeeze-out remaining MorphoSys shareholders
MorphoSys and Novartis sign delisting agreement
Novartis Aims for Full Acquisition of MorphoSys